TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12510011
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day for 12 weeks
Study: 19673941
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg/day for 12 weeks
Study: 9551703
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg on day 1 and 200 mg on days 2-4)
Study: 18034211
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg IV once daily followed by oral moxifloxacin 400 mg once daily
Study: 18034211
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g IV once daily followed by oral cefuroxime axetil 500 mg twice daily
Study: 15308999
Drug: Post-menopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-menopausal hormone therapy
Study: 10886122
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion after oral, jejunal, and ileal applications
Study: 10886122
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion after rectal administration
Study: 23177313
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin (high-dose)
Study: 18444791
Drug: Telavancin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin (10 mg/kg intravenously every 24 h)
Study: 18444791
Drug: Vancomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1 g intravenously every 12 h)
Study: 16818273
Drug: Deferasirox (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (10 or 20 mg/kg)
Study: 14501611
Drug: Transdermal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐estradiol (50 microg/day) and medroxyprogesterone acetate (10 mg/day) for 12 days per cycle
Study: 11126524
Drug: Lercanidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine (10 mg once a day)
Study: 7006664
Drug: oral melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral melphalan with prednisone (M & P)
Study: 25415292
Drug: 4-drug regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-drug regimen
Study: 7006664
Drug: stop all
Approvals — FDA: no, EMA: no, PMDA: no
Description: stop all treatment until evidence of relapse
Study: 26153168
Drug: Vaginal cream
Normalized name: VAGINAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal cream mixed of yogurt and honey
Study: 21300929
Drug: ABT-751 with
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-751 with pemetrexed (200 mg)
Study: 17053334
Drug: Behavioral inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral inpatient treatment (n = 130)
Study: 18061416
Drug: Beer (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beer (3 cans daily, 40 g ethanol)
Study: 15334426
Drug: Lumiracoxib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 400 mg once daily
Study: 2291870
Drug: Nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 10 mg
Study: 20840194
Drug: Reconstituted HDL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted HDL (rHDL) infusion
Study: 18479177
Drug: Intravenous lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lornoxicam (Xefo, 2 mL, 8 mg) with normal saline 20 mL wound infiltration
Study: 2004846
Drug: Intermittent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-dose cyclosporin A therapy for 6 days with each course of anti-CEA (3 patients)
Study: 2004846
Drug: Repeated therapy
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated therapy with 131I anti-CEA
Study: 10442208
Drug: Tilidine/naloxone liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine/naloxone liquid formulation (50 mg/4 mg)
Study: 10442208
Drug: Ethanol-containing reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol-containing reference preparation (50 mg/4 mg)
Study: 7880100
Drug: Best conventional
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best conventional treatment
Study: 2720017
Drug: fenfluramine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenfluramine (60 mg)
Study: 22093888
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) group; infusion of 0.4 µg×kg(‐1)×h(‐1) for 10 min, adjusted between 0.2 and 0.4 µg×kg(‐1)×h(‐1) to maintain BIS around 80.
Study: 16464383
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled intravenous ketamine analgesia (PCIKA) with intravenous small dose ketamine (20 g/L + droperidol 50 mg/L)
Study: 16464383
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled intravenous ketamine and fentanyl analgesia (PCIKFA) with intravenous small dose ketamine (10 g/L + fentanyl 5 mg/L + droperidol 50 mg/L)
Study: 12749433
Drug: TGZ-600 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGZ-600 (600 mg/day)
Study: 12749433
Drug: TGZ-150 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGZ-150 (150 mg/day)
Study: 12749433
Drug: TGZ-300 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGZ-300 (300 mg/day)
Study: 19691907
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg paroxetine
Study: 30076437
Drug: Microsurgical laminotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsurgical laminotomy (ML)
Study: 16041153
Drug: Pravastatin 10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10-20 mg/day
Study: 10443837
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection to thyroarytenoid muscles only
Study: 10443837
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection to both thyroarytenoid muscles and strap muscles
Study: 2148176
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg and 20 mg
Study: 30783814
Drug: Afatinib dose
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib dose reduction (< 40 mg/day)
Study: 24325051
Drug: Wenxin Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wenxin Granule (WG), 9 g each time, three times daily for 90 days
Study: 24325051
Drug: Routine therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapies (ACEI and metoprolol)
Study: 18005494
Drug: Active Cognitive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Cognitive Therapy for Early Psychosis (ACE)
Study: 29310679
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily
Study: 7582381
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (azathioprine + prednisolone)
Study: 21211641
Drug: 3 years
Normalized name: NanoVM 1-3 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years of specific immunotherapy (IT3)
Study: 21211641
Drug: 5 years
Normalized name: Dymadon 5 Years Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 years of specific immunotherapy (IT5)
Study: 28318748
Drug: Tablet distraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet distraction provided by a child life specialist
Study: 15115901
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral oestradiol for 3 months
Study: 20881947
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release d-amphetamine (SR-AMP) 0, 30, and 60 mg/day
Study: 31721398
Drug: Oxycodone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone + Naloxegol
Study: 31323005
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (GnRHa only)
Study: 27743396
Drug: Subcrestal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcrestal implants placed 2 mm below the alveolar crest
Study: 23700728
Drug: Modified Devine's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Devine's operation (treatment group)
Study: 9174317
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus Morphine (0.1 mL of 0.5 mg of morphine plus lidocaine 1%)
Study: 23148715
Drug: Mixed (group-individual)
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed (group-individual) modality intervention incorporating Motivational Interviewing, Dialectical Behavior Therapy skills, and job-related skills.
Study: 16545641
Drug: Albuterol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (5 microg/min)
Study: 12861468
Drug: Budesonide/formoterol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol fixed dosing
Study: 6715084
Drug: 2% solution
Normalized name: Lidomar 2% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% solution of lignocaine iontophoresed for 10 min at 1‐2.5 mA
Study: 24843782
Drug: Metformin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1,000 mg daily
Study: 22142309
Drug: PKEK treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PKEK treatment
Study: 22142309
Drug: PKEK added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PKEK added to SAP-containing preparation
Study: 22142309
Drug: PKEK+SAP formulation
Normalized name: Bambusa vulgaris sap extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PKEK+SAP formulation
Study: 7666093
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus AS101
Study: 2495983
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate 50 mg
Study: 3904873
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate 100 mg
Study: 919799
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy only (group 2)
Study: 28588322
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus gemcitabine (G)
Study: 28588322
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus gemcitabine and nab-paclitaxel (G+NP)
Study: 28588322
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus gemcitabine and vinorelbine (G+V)
Study: 22422103
Drug: Immunotherapy alone
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy alone
Study: 23561229
Drug: levomilnacipran SR
Normalized name: Levomilnacipran
DrugBank: Levomilnacipran (DB08918)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: levomilnacipran SR 40 mg
Study: 23561229
Drug: levomilnacipran SR
Normalized name: Levomilnacipran
DrugBank: Levomilnacipran (DB08918)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: levomilnacipran SR 80 mg
Study: 23561229
Drug: levomilnacipran SR
Normalized name: Levomilnacipran
DrugBank: Levomilnacipran (DB08918)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: levomilnacipran SR 120 mg
Study: 11051055
Drug: Glimepiride administration
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride administration
Study: 3963030
Drug: Flurbiprofen (73
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (73 patients) administered two, three, or four times a day in total daily doses of 100, 150, or 200 mg
Study: 3963030
Drug: Aspirin (74
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (74 patients) administered two, three, or four times a day in total daily doses of 2,000, 3,000, or 4,000 mg
Study: 6121605
Drug: lormetazepam 2
Normalized name: lormetazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lormetazepam 2 mg
Study: 24078500
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac sodium (1 mg/kg) 45 minutes before the procedure
Study: 24078500
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (10 gm) applied locally 45 minutes before the procedure
Study: 24078500
Drug: Diclofenac diethylamine
Normalized name: diclofenac diethylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac diethylamine gel (15 gm) applied locally 45 minutes before the procedure
Study: 11781629
Drug: 1.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/day of eicosapentaenoic acid (EPA) orally from 3 weeks before to about 180 days after transplantation
Study: 11781629
Drug: 1.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/day of eicosapentaenoic acid (EPA)
Study: 7923485
Drug: Continent patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continent patients with rectal prolapse
Study: 29705992
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics followed by oral antibiotics
Study: 17057294
Drug: Vitamins and
Normalized name: multivitamins and iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins and dietary supplements (vit. E, beta-carotene, acetylsalicylic acid) in combination with treatment measures
Study: 12696990
Drug: Orlistat, 120
Normalized name: Orlistat, 120 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat, 120 mg three times daily
Study: 12696990
Drug: Standard diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diabetes therapy and weight management alone (Control)
Study: 10702450
Drug: Epidural droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural droperidol 0.0 mg
Study: 9080303
Drug: cM-T412 (chimeric
Approvals — FDA: no, EMA: no, PMDA: no
Description: cM-T412 (chimeric CD4 monoclonal antibody)
Study: 3812881
Drug: Conventional single-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional single-site intramuscular regimen
Study: 3812881
Drug: 0.25 ml
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml doses of diploid cell vaccine given subcutaneously at eight sites
Study: 3812881
Drug: Standard single-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard single-site diploid cell vaccine
Study: 3812881
Drug: Eight-site intradermal
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight-site intradermal regimen of diploid cell vaccine
Study: 31455312
Drug: Hand therapy
Normalized name: Octinoxate 3.00 mL in 75 mL / Avobenzone 1.5 mL in 75 mL TOPICAL CREAM [Botanics Daily Hand Therapy Sunscreen SPF 10]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand therapy
Study: 30400892
Drug: Oscillating-rotating toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oscillating-rotating toothbrush (Oral-B Vitality)
Study: 26987887
Drug: Plant-based quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant-based quadrivalent virus-like particle (QVLP) vaccine
Study: 19890274
Drug: Epoetin-alfa treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin-alfa treatment with low hemoglobin target (11.3 g/l)
Study: 18772726
Drug: Codeine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (2 mg/kg; maximum 120 mg)
Study: 12439084
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg x kg(‐1))
Study: 11235558
Drug: Albendazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (10 mg/kg.day for 5 days)
Study: 27296978
Drug: ARTAS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ARTAS intervention for drug users with a treatment history
Study: 17420604
Drug: Yogurt containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt containing 3.0 or 4.0 g of KM‐CW/d for 8 weeks
Study: 7861019
Drug: Zidovudine (nucleoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (nucleoside reverse transcriptase inhibitor)
Study: 7011526
Drug: Modern low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modern low-dose mammography screening
Study: 31972587
Drug: Topical insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical insulin (Actrapid) 10 units (0.1 mL) in 1 mL of normal saline, applied twice daily.
Study: 31972587
Drug: Topical normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical normal saline (placebo).
Study: 28624041
Drug: Replacing saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacing saline solution during surgery (experimental group)
Study: 22863242
Drug: Achieved iPTH
Normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-52816 Featuring You Hydrating Skin Enhancing Tint SPF30-390 ACHIEVE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achieved iPTH ≤ 300 pg/mL
Study: 19085634
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1.5 g daily)
Study: 17726611
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg in 1 ml subcutaneously twice a week for 2 weeks)
Study: 2569993
Drug: 8 mg/day
Normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/day azelastine once daily
Study: 956103
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ascorbic acid
Study: 30401528
Drug: Aspirin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (low European System for Cardiac Operative Risk Evaluation score)
Study: 19813461
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of ramipril (10 mg)
Study: 21467283
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) 0.625 mg/d
Study: 15213206
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens plus medroxyprogesterone acetate (MPA) 0.625 mg/d + 2.5 mg/d
Study: 7882462
Drug: Vinfosiltine (S12363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinfosiltine (S12363) at 0.3 mg/m2 given weekly
Study: 391623
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetylsalicylic acid and dipyridamole
Study: 30819510
Drug: Nemonoxacin 500
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 500 mg single dose
Study: 18445072
Drug: Pharmaceutical company
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical company involvement
Study: 15483465
Drug: Indinavir (IDV)/Ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (IDV)/Ritonavir (RTV) at 800/200 mg (arm A)
Study: 15483465
Drug: Indinavir (IDV)/Ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (IDV)/Ritonavir (RTV) at 400/400 mg (arm B)
Study: 8018144
Drug: Zidovudine therapy
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine therapy
Study: 31107775
Drug: Nurse-led cognitive
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led cognitive behavioral intervention (five monthly in-home sessions and telephone consultations)
Study: 23351824
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA 1 g/daily
Study: 21283919
Drug: Cetaphil UVA/UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetaphil UVA/UVB Defense SPF 50 sunscreen exposed to natural sunlight (4 doses ranging from 2–6 MED)
Study: 17966178
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IPL (580-980 nm) and bipolar radiofrequency (RF) energies
Study: 7906386
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg of zidovudine per day
Study: 7906386
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of zidovudine per day
Study: 25803346
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (medical group; n=53)
Study: 17223985
Drug: Tibolone at
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone at a dose of 2.5‐7.5 mg/day
Study: 9555445
Drug: Self-applied breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-applied breathing and guided imagery relaxation techniques, separately and in combination, and a reinforcement tool
Study: 31268131
Drug: TRF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRF plus 3 g/d HMB (TRFHMB)
Study: 25449504
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg adenosine (ADO)
Study: 23575051
Drug: Oral Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tranexamic Acid (250 mg twice a day for three months)
Study: 23575051
Drug: Routine topical
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine topical therapies